Images of the brain using FDG-PET can accurately detect Alzheimer's disease in patients presenting with primary progressive aphasia or corticobasal syndrome as focal onset dementias, according to a study published in The Journal of Nuclear Medicine.
Authors from the United States, Japan, and Australia sought to determine the accuracy of FDG-PET metabolic imaging when detecting Alzheimer’s disease among patients with primary progressive aphasia or corticobasal syndrome.
A total of 94 subjects participated in the study, including subjects who were diagnosed with:
• Logopenic aphasia, 19 subjects
• Non-fluent aphasia, 16 subjects
• Semantic aphasia, 13 subjects
• Corticobasal syndrome, 14 subjects
• Alzheimer's disease, 24 subjects
All underwent F18-FDG metabolic and C11-PiB amyloid PET brain imaging. The FDG-PET scans that were read with Neurostat 3D-SSP software displays were classified as Alzheimer's disease or other by readers blind to the clinical assessments and PiB-PET results.
The results showed 84% accuracy for subjects who were diagnosed with Alzheimer’s disease based on FDG-PET results. However, diagnoses based on clinical assessment resulted in only 65% conventional and 67% balanced accuracy.
The researchers concluded, “Brain FDG-PET scans read with Neurostat 3D-SSP displays accurately detect Alzheimer's disease in patients presenting with primary progressive aphasia or corticobasal syndrome as focal onset dementias. In these diagnostically challenging cohorts, FDG-PET imaging can provide more accurate diagnoses enabling more appropriate therapy.”